Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
Liminatus Pharma, Inc., a Nasdaq-listed biopharmaceutical company, has entered a warrant exercise agreement resulting in $1.9 million in gross proceeds. Existing warrants to purchase shares were exercised, with holders receiving new unregistered warrants contingent on stockholder approval. The transaction, facilitated by Maxim Group LLC, aims to pr…